2025
Standard complete blood count to predict long‐term outcomes in febrile infection–related epilepsy syndrome (FIRES): A multicenter study
Guillemaud M, Hanin A, Riviello J, Chavez M, Batra A, Berry M, Bisulli F, Castillo‐Pinto C, Cobos‐Hernandez C, Demeret S, Eschbach K, Farias‐Moeller R, Fields M, Gaspard N, Gerard E, Gofton T, Gopaul M, Gruen M, Jimenez A, Kazazian K, Kim M, Mansour M, Marcuse L, Marois C, Morales M, Muccioli L, Pasini E, Pham M, Rosas S, Struck A, Torcida N, Wainwright M, Yoo J, Muscal E, Navarro V, Hirsch L, Lai Y. Standard complete blood count to predict long‐term outcomes in febrile infection–related epilepsy syndrome (FIRES): A multicenter study. Epilepsia 2025 DOI: 10.1111/epi.18605.Peer-Reviewed Original ResearchFebrile infection-related epilepsy syndromeMonocyte-to-lymphocyte ratioNeutrophil-to-lymphocyte ratioComplete blood countNew-onset refractory status epilepticusSecond-line immunotherapyUnfavorable outcomeBlood countComplete blood count levelsHigh red cell distribution widthEpilepsy syndromesTreatment phaseFirst-line immunotherapyInitiation of immunotherapyRed cell distribution widthRefractory status epilepticusComplete blood count dataCell distribution widthLong-term outcomesIntensive care unitSubtypes of leukocytesLeave-one-patient-outMulticenter studyStatus epilepticusImmunotherapySpatial transcriptomic analysis of immune checkpoint blockade response in triple negative breast cancers with tertiary lymphoid structures
Mebane R, Noel T, Ing N, Gouin K, Shah A, Zitser D, Martinez A, Gupta G, Demaria S, Galluzzi L, Ho A, McArthur H, Shiao S, Knott S. Spatial transcriptomic analysis of immune checkpoint blockade response in triple negative breast cancers with tertiary lymphoid structures. IScience 2025, 28: 112808. PMID: 40599321, PMCID: PMC12209978, DOI: 10.1016/j.isci.2025.112808.Peer-Reviewed Original ResearchTertiary lymphoid structuresLymphoid structuresRadiation therapyImmunotherapy responseImmune checkpoint blockade responseTriple negative breast cancerCancer immunotherapy responseNegative breast cancerCancer cell removalTumor bedBlockade responseMalignant cellsBreast tumorsImmune activationMacrophage infiltrationPembrolizumabBreast cancerLongitudinal biopsiesSpatial transcriptomic analysisTumorTherapyCancerInfiltrationCell removalImmunotherapyAdvance care planning documentation prior to end-of-life systemic therapy: A single institution retrospective review.
Xiang J, Wiese B, Patlovich K, Taylor J, Adelson K, Ratan R. Advance care planning documentation prior to end-of-life systemic therapy: A single institution retrospective review. Journal Of Clinical Oncology 2025, 43 DOI: 10.1200/jco.2025.43.16_suppl.e24031.Peer-Reviewed Original ResearchSystemic anticancer therapyMonths of lifeTargeted therapyDose of treatmentAdvance care planning notesFinal treatmentAdvance care planningEnd-of-lifeHigher risk of mortalityDocumented discussionAssociated with decreased quality of lifeRisk of mortalityAssociated with decreased qualityMetastatic diseaseHigh healthcare useInpatient settingSolid tumorsRetrospective studyMD AndersonCellular therapyMedical oncologistsAnticancer therapyImmunotherapyTherapyPatientsOne-Two Punch: Combining Chemotherapy and Immunotherapy to Decrease Radiation Dose and Related Toxicity in Children and Adolescents with Nasopharyngeal Carcinoma.
Dholaria H, Tsetlina V, Simpson S, Gillies E, Eswaran N, Rodriguez-Galindo C, Schultz K, Chen K, Wu C, Krasin M, Roemer T, Christiansen H, Piao J, Laetsch T, Pashankar F, Kontny U, Gartrell R. One-Two Punch: Combining Chemotherapy and Immunotherapy to Decrease Radiation Dose and Related Toxicity in Children and Adolescents with Nasopharyngeal Carcinoma. Clinical Cancer Research 2025, of1-of9. PMID: 40445588, DOI: 10.1158/1078-0432.ccr-24-3546.Peer-Reviewed Original ResearchGerman Society of Pediatric Oncology and HematologyChildren's Oncology GroupNasopharyngeal carcinomaClinical trialsAnti-PD-1 therapyRadiation doseDecreased radiation dosePediatric clinical trialsSevere side effectsConcomitant chemotherapyAdjuvant immunotherapyInduction chemotherapyOncology GroupRelated toxicityTreated patientsExcellent survivalSide effectsChemotherapyLate effectsLong-term effectsImmunotherapyCarcinomaClinical priorityDoseResponse-adaptiveUpdates on radiotherapy-immunotherapy combinations: Proceedings of 8th Annual ImmunoRad Conference
Talebi F, Gregucci F, Ahmed J, Chetrit N, Brown B, Chan T, Chand D, Constanzo J, Demaria S, Gabrilovich D, Golden E, Godkin A, Guha C, Gupta G, Hasan A, Herrera F, Kaufman H, Li D, Melcher A, McDonald S, Merghoub T, Monjazeb A, Paris S, Pitroda S, Sadanandam A, Schaue D, Santambrogio L, Szapary P, Sage J, Welsh J, Wilkins A, Young K, Wennerberg E, Zitvogel L, Galluzzi L, Deutsch E, Formenti S. Updates on radiotherapy-immunotherapy combinations: Proceedings of 8th Annual ImmunoRad Conference. OncoImmunology 2025, 14: 2507856. PMID: 40401900, PMCID: PMC12101595, DOI: 10.1080/2162402x.2025.2507856.Peer-Reviewed Original ResearchUrine Tumor DNA to Stratify the Risk of Recurrence in Patients Treated with Atezolizumab for Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer
St-Laurent M, Singh P, McConkey D, Lucia M, Koshkin V, Stratton K, Bivalacqua T, Kassouf W, Porten S, Bangs R, Plets M, Thompson I, Meeks J, Caruso V, Ward C, Mazzarella B, Phillips K, Bicocca V, Levin T, Lerner S, Black P. Urine Tumor DNA to Stratify the Risk of Recurrence in Patients Treated with Atezolizumab for Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer. European Urology 2025 PMID: 40404526, DOI: 10.1016/j.eururo.2025.03.023.Peer-Reviewed Original ResearchNon-muscle-invasive bladder cancerUrine tumor DNAEvent-free survivalTumor DNABladder cancerBCG-unresponsive NMIBCPatients treated with atezolizumabRisk of treatment failureClinical evidence of diseaseRisk of recurrenceEvidence of diseaseSystemic immunotherapyTreatment failureTherapeutic decisionsClinical evidencePatientsUrine samplesAtezolizumabBaselineCancerUrineTreatmentRiskImmunotherapySWOGClinical Aspects of Gestational Trophoblastic Disease
Clark M, Ratner E, Schwartz P. Clinical Aspects of Gestational Trophoblastic Disease. 2025, 253-260. DOI: 10.1007/978-3-031-83545-2_15.Peer-Reviewed Original ResearchMolar pregnancyRefractory to initial treatmentIntermediate trophoblastic tumorInvasive molar pregnancyGestational trophoblastic diseaseComplex clinical scenariosRate of regressionTrophoblastic tumorTrophoblastic diseasePrompt diagnosisInitial treatmentClinical entityClinical scenariosPregnancyCenters of excellenceDiseaseChoriocarcinomaImmunotherapySurgeryTumorDiagnosisPD-L1 and the dawn of modern cancer immunotherapy
Chen L. PD-L1 and the dawn of modern cancer immunotherapy. Nature Medicine 2025, 31: 1378-1378. PMID: 40325200, DOI: 10.1038/s41591-025-03698-4.Peer-Reviewed Original ResearchIdentification of post-translationally modified MHC class I-associated peptides as potential cancer immunotherapeutic targets
Mahoney K, Reser L, Ruiz Cuevas M, Abelin J, Shabanowitz J, Hunt D, Malaker S. Identification of post-translationally modified MHC class I-associated peptides as potential cancer immunotherapeutic targets. Molecular & Cellular Proteomics 2025, 100971. PMID: 40239839, DOI: 10.1016/j.mcpro.2025.100971.Peer-Reviewed Original ResearchCirculating cytotoxic T-cellsMHC class I processing pathwayClass I processing pathwayCancer immunotherapy targetCytotoxic T cellsCancer immunotherapeutic targetsVaccine development effortsModern immunotherapyImmunotherapy targetMHC-associated peptidesImmunotherapeutic targetT cellsMalignant cellsAntigen presentationAberrant signalingMHC-peptideMass spectrometry-based technologiesCancerMHCPost-translational modificationsDysregulationIdentification of post-translationallyPeptideImmunotherapyPathwayPreclinical Models of Solid Cancers for Testing Cancer Immunotherapies
Exposito F, Connolly K, Tang T, Chiorazzi M, Hunt B, Cardenas J, Nguyen D, Joshi N, Politi K. Preclinical Models of Solid Cancers for Testing Cancer Immunotherapies. Annual Review Of Cancer Biology 2025, 9: 285-305. DOI: 10.1146/annurev-cancerbio-062822-024810.Peer-Reviewed Original ResearchResponse to immunotherapyDevelopment of immunotherapyStandard treatment optionCancer immunotherapy drugsCancer-immune interactionsNumerous cancer typesImmunotherapy resistanceImmunotherapy drugsCancer immunologyPreclinical modelsTreatment optionsMouse modelImmunotherapyCancer typesAdvanced in vitro systemsHuman modelTherapyCancerMiceImmunologyDrugMicroglial reprogramming: a potential new frontier in enhancing immunotherapy for melanoma brain metastasis
Savion‐Gaiger N, Bar‐Ziv D, Kluger H. Microglial reprogramming: a potential new frontier in enhancing immunotherapy for melanoma brain metastasis. Molecular Oncology 2025, 19: 1291-1294. PMID: 40111148, PMCID: PMC12077281, DOI: 10.1002/1878-0261.70028.Peer-Reviewed Original ResearchConceptsMelanoma brain metastasesBrain metastasesSites of metastatic disseminationHuman brain metastasesAdvanced melanomaEnhance immunotherapyMurine studiesTumor microenvironmentMetastatic disseminationMyeloid cellsMelanoma cellsMelanomaMetastasisMicroglial cellsPotential new frontiersCellsBrainImmunotherapyTumorMicroenvironmentTop advances of the year: Small cell lung cancer
Shields M, Chiang A, Byers L. Top advances of the year: Small cell lung cancer. Cancer 2025, 131: e35770. PMID: 40040254, DOI: 10.1002/cncr.35770.Peer-Reviewed Original ResearchConceptsSmall cell lung cancerExtensive-stage small cell lung cancerCell lung cancerLung cancerLimited-stage small cell lung cancerFrequency of disease relapseTiming of immunotherapyCancer-related mortalityLong-term survivalAntibody-drug conjugatesNeuroendocrine subtypeDisease relapseAggressive biologyMetastatic spreadInferior outcomesImproved survivalImmunotherapyTherapeutic breakthroughConsolidation treatmentCancerPrecision medicineBiomarker selectionSurvivalLurbinectedinForward-thinking approachProceedings of the National Cancer Institute Workshop on combining immunotherapy with radiotherapy: challenges and opportunities for clinical translation
Morris Z, Demaria S, Monjazeb A, Formenti S, Weichselbaum R, Welsh J, Enderling H, Schoenfeld J, Brody J, McGee H, Mondini M, Kent M, Young K, Galluzzi L, Karam S, Theelen W, Chang J, Huynh M, Daib A, Pitroda S, Chung C, Serre R, Grassberger C, Deng J, Sodji Q, Nguyen A, Patel R, Krebs S, Kalbasi A, Kerr C, Vanpouille-Box C, Vick L, Aguilera T, Ong I, Herrera F, Menon H, Smart D, Ahmed J, Gartrell R, Roland C, Fekrmandi F, Chakraborty B, Bent E, Berg T, Hutson A, Khleif S, Sikora A, Fong L. Proceedings of the National Cancer Institute Workshop on combining immunotherapy with radiotherapy: challenges and opportunities for clinical translation. The Lancet Oncology 2025, 26: e152-e170. PMID: 40049206, DOI: 10.1016/s1470-2045(24)00656-9.Peer-Reviewed Original ResearchConceptsAnti-tumor immune responseDelivery of radiotherapyTumor immune recognitionSelection of immunotherapyBiomarker-guided approachesNational Cancer Institute workshopClinical trial dataImmunotherapy combinationsClinical responseImprove patient outcomesPreclinical modelsPatient selectionRadiotherapyImmunotherapyClinical endpointsClinical dataClinical studiesImmune recognitionImmune responseImmune effectsAnimal studiesClinical translationPatient outcomesTrial dataNegative trialsHIF regulates multiple translated endogenous retroviruses: Implications for cancer immunotherapy
Jiang Q, Braun D, Clauser K, Ramesh V, Shirole N, Duke-Cohan J, Nabilsi N, Kramer N, Forman C, Lippincott I, Klaeger S, Phulphagar K, Chea V, Kim N, Vanasse A, Saad E, Parsons T, Carr-Reynolds M, Carulli I, Pinjusic K, Jiang Y, Li R, Syamala S, Rachimi S, Verzani E, Stevens J, Lane W, Camp S, Meli K, Pappalardi M, Herbert Z, Qiu X, Cejas P, Long H, Shukla S, Van Allen E, Choueiri T, Churchman L, Abelin J, Gurer C, MacBeath G, Childs R, Carr S, Keskin D, Wu C, Kaelin W. HIF regulates multiple translated endogenous retroviruses: Implications for cancer immunotherapy. Cell 2025, 188: 1807-1827.e34. PMID: 40023154, PMCID: PMC11988688, DOI: 10.1016/j.cell.2025.01.046.Peer-Reviewed Original ResearchClear cell renal cell carcinomaCancer immunotherapyAntigen-specific T cell responsesAllogeneic stem cell transplantationEndogenous retrovirusesClear cell renal cell carcinoma patientsLow mutational burdenCell renal cell carcinomaStem cell transplantationT cell responsesRenal cell carcinomaVHL tumor suppressor geneTumor suppressor geneHLA-bound peptidesEndogenous retrovirus expressionNon-ccRCCCell transplantationMutational burdenSpontaneous regressionCell carcinomaT cellsCase reportSuppressor geneHIF transcription factorsImmunotherapySensitive detection of synthetic response to cancer immunotherapy driven by gene paralog pairs
Dong C, Zhang F, He E, Ren P, Verma N, Zhu X, Feng D, Cai J, Zhao H, Chen S. Sensitive detection of synthetic response to cancer immunotherapy driven by gene paralog pairs. Patterns 2025, 6: 101184. PMID: 40182179, PMCID: PMC11963098, DOI: 10.1016/j.patter.2025.101184.Peer-Reviewed Original ResearchParalogous gene pairsParalogous pairsChimeric antigen receptor T cellsResponse to cancer immunotherapyDouble knockoutCancer immunotherapy responseGene pairsCheckpoint blockadeGenome-wide screenImmunotherapy efficacyCancer immunotherapyEnhance immunotherapyImmunotherapy responseImmunotherapy effectT cellsImmunotherapyCancer treatmentIndividual genesCRISPR screensEnrichment analysisParalogsCancerTreatmentCombined targetFunctional significanceAuthor Correction: Multiplexed inhibition of immunosuppressive genes with Cas13d for combinatorial cancer immunotherapy
Zhang F, Chow R, He E, Dong C, Xin S, Mirza D, Feng Y, Tian X, Verma N, Majety M, Zhang Y, Wang G, Chen S. Author Correction: Multiplexed inhibition of immunosuppressive genes with Cas13d for combinatorial cancer immunotherapy. Nature Biotechnology 2025, 1-1. PMID: 39901026, DOI: 10.1038/s41587-025-02576-1.Peer-Reviewed Original ResearchMitochondrial succinate feeds T cell exhaustion in cancer
Galluzzi L, Guilbaud E, Garg A. Mitochondrial succinate feeds T cell exhaustion in cancer. Cancer Cell 2025, 43: 168-170. PMID: 39933894, DOI: 10.1016/j.ccell.2025.01.005.Peer-Reviewed Original ResearchMultiplexed inhibition of immunosuppressive genes with Cas13d for combinatorial cancer immunotherapy
Zhang F, Chow R, He E, Dong C, Xin S, Mirza D, Feng Y, Tian X, Verma N, Majety M, Zhang Y, Wang G, Chen S. Multiplexed inhibition of immunosuppressive genes with Cas13d for combinatorial cancer immunotherapy. Nature Biotechnology 2025, 1-14. PMID: 39820813, DOI: 10.1038/s41587-024-02535-2.Peer-Reviewed Original ResearchAdeno-associated virusTumor microenvironmentImmunosuppressive genesAntitumor efficacyCD8+ T cell infiltrationIn vivo antitumor efficacyCombinatorial cancer immunotherapyImmunosuppressive tumor microenvironmentSyngeneic tumor modelsT cell infiltrationTumor microenvironment remodelingMulti-agent combinationsMultiple tumor typesAntitumor immunityCombinatorial immunotherapyOptimal immunotherapyCancer immunotherapyGene alterationsTumor typesTumor modelReduced neutrophilLiver toxicityShRNA treatmentWhole-transcriptome profilingImmunotherapyAutogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial
Lopez J, Powles T, Braiteh F, Siu L, LoRusso P, Friedman C, Balmanoukian A, Gordon M, Yachnin J, Rottey S, Karydis I, Fisher G, Schmidt M, Schuler M, Sullivan R, Burris H, Galvao V, Henick B, Dirix L, Jaeger D, Ott P, Wong K, Jerusalem G, Schiza A, Fong L, Steeghs N, Leidner R, Rittmeyer A, Laurie S, Gort E, Aljumaily R, Melero I, Sabado R, Rhee I, Mancuso M, Muller L, Fine G, Yadav M, Kim L, Leveque V, Robert A, Darwish M, Qi T, Zhu J, Zhang J, Twomey P, Rao G, Low D, Petry C, Lo A, Schartner J, Delamarre L, Mellman I, Löwer M, Müller F, Derhovanessian E, Cortini A, Manning L, Maurus D, Brachtendorf S, Lörks V, Omokoko T, Godehardt E, Becker D, Hawner C, Wallrapp C, Albrecht C, Kröner C, Tadmor A, Diekmann J, Vormehr M, Jork A, Paruzynski A, Lang M, Blake J, Hennig O, Kuhn A, Sahin U, Türeci Ö, Camidge D. Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial. Nature Medicine 2025, 31: 152-164. PMID: 39762422, PMCID: PMC11750724, DOI: 10.1038/s41591-024-03334-7.Peer-Reviewed Original ResearchConceptsCD8+ T cellsAdvanced solid tumorsT cellsSolid tumorsCirculating CD8+ T cellsEfficacy of cancer immunotherapyTumor-infiltrating T cellsStimulate T cell responsesResponse to immunotherapyT cell responsesPreliminary antitumor activityPhase 1 studyPhase 1 trialDose escalationPretreated patientsCancer immunotherapyEvaluation of pharmacokineticsCD4+Tumor lesionsTreatment initiationTumor tissuesAtezolizumabClinical activityDisease characteristicsImmunotherapy
2024
A novel pharmacological entity toward integrated multimodal immunotherapy
Sirera R, Beltrán-Visiedo M, Galluzzi L. A novel pharmacological entity toward integrated multimodal immunotherapy. Trends In Pharmacological Sciences 2024, 46: 95-97. PMID: 39721827, DOI: 10.1016/j.tips.2024.12.001.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply